Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: Current status and future perspectives

Seminars in Oncology

Volumn 39, Issue 4, 2012, Pages 493-502

  Zhu, Andrew X ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; BELINOSTAT; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CEDIRANIB; CETUXIMAB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GANETESPIB; GEFITINIB; LAPATINIB; LENALIDOMIDE; LENVATINIB; LINIFANIB; MAPATUMUMAB; ORANTINIB; PAZOPANIB; RAMUCIRUMAB; RAPAMYCIN; RESMINOSTAT; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; UNINDEXED DRUG; VORINOSTAT;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFERENCE PAPER; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; HYPOPIGMENTATION; LIVER CELL CARCINOMA; MALAISE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; CARCINOMA, HEPATOCELLULAR; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84864480565     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.05.014     Document Type: Conference Paper

References (65)

1. J.M. Llovet, S. Ricci, V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
2. A.X. Zhu, D.G. Duda, D.V. Sahani, R.K. Jain HCC and angiogenesis: possible targets and future directions Nat Rev Clin Oncol 8 2011 292 301
3. L. Messerini, L. Novelli, C.E. Comin Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma J Clin Pathol 57 2004 867 871
4. H. Miura, T. Miyazaki, M. Kuroda Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma J Hepatol 27 1997 854 861
5. R. Yamaguchi, H. Yano, A. Iemura, S. Ogasawara, M. Haramaki, M. Kojiro Expression of vascular endothelial growth factor in human hepatocellular carcinoma Hepatology 28 1998 68 77
6. R. Yamaguchi, H. Yano, Y. Nakashima Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues Oncol Rep 7 2000 725 729
7. Y. Chao, C.P. Li, G.Y. Chau Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery Ann Surg Oncol 10 2003 355 362
8. K.S. Jeng, I.S. Sheen, Y.C. Wang Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study World J Gastroenterol 10 2004 643 648
9. R.T. Poon, J.W. Ho, C.S. Tong, C. Lau, I.O. Ng, S.T. Fan Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma Br J Surg 91 2004 1354 1360
10. J.M. Llovet, C. Pena, C. Lathia, M. Shan, G. Meinhardt, J. Bruix Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2290 2300
11. A. Arora, E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther 315 2005 971 979
12. D.B. Mendel, A.D. Laird, X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
13. T. Pawson Regulation and targets of receptor tyrosine kinases Eur J Cancer 38 Suppl 5 2002 S3 S10
14. S. Faivre, E. Raymond, E. Boucher Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
15. D. Koeberle, M. Montemurro, P. Samaras Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): a multicenter phase II trial (SAKK 77/06 and SASL 23) J Clin Oncol 27 Suppl 2009 15s (abstract 4591)
16. A.X. Zhu, D.V. Sahani, D.G. Duda Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study J Clin Oncol 27 2009 3027 3035
17. D. Koeberle, M. Montemurro, P. Samaras Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06) Oncologist 15 2010 285 292
18. A.L. Cheng, Y.K. Kang, D. Lin Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) J Clin Oncol 29 Suppl 2011 (abstract 4000)
19. H. Huynh, V.C. Ngo, J. Fargnoli Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma Clin Cancer Res 14 2008 6146 6153
20. J.W. Park, R.S. Finn, J.S. Kim Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
21. R.S. Finn, Y.K. Kang, M. Mulcahy Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2090 2098
22. H. Toh, P. Chen, B.I. Carr A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis J Clin Oncol 27 Suppl 2009 15s (abstract 4581)
23. A.X. Zhu, R.S. Finn, M.F. Mulcahy A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC) J Clin Oncol 28 Suppl 2010 15s (abstract 4083)
24. A.B. Siegel, E.I. Cohen, A. Ocean Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma J Clin Oncol 26 2008 2992 2998
25. S.R. Alberts, T.R. Fitch, G.P. Kim Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial Am J Clin Oncol 2011 Mar 17 [Epub ahead of print]
26. T. Yau, P.J. Chen, P. Chan Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics Clin Cancer Res 17 2011 6914 6923
27. F. Kanai, H. Yoshida, R. Tateishi A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma Cancer Chemother Pharmacol 67 2011 315 324
28. H. Safran, K. Charpentier, A. Kaubisch Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib J Clin Oncol 29 Suppl 2011 (abstract 4048)
29. K. Okita, H. Kumada, K. Ikeda Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): initial assessment of response rate J Clin Oncol 30 Suppl 4 2012 (abstract 320)
30. C.R. Carlin, D. Simon, J. Mattison, B.B. Knowles Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines Mol Cell Biol 8 1988 25 34
31. K. Harada, G. Shiota, H. Kawasaki Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma Liver 19 1999 318 325
32. Y. Ito, T. Takeda, S. Higashiyama Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study Oncol Rep 8 2001 903 907
33. S. Kira, T. Nakanishi, S. Suemori, M. Kitamoto, Y. Watanabe, G. Kajiyama Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma Liver 17 1997 177 182
34. A. Kiss, N.J. Wang, J.P. Xie, S.S. Thorgeirsson Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas Clin Cancer Res 3 1997 1059 1066
35. Y.C. Yeh, J.F. Tsai, L.Y. Chuang Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma Cancer Res 47 1987 896 901
36. A.X. Zhu, K. Stuart, L.S. Blaszkowsky Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma Cancer 110 2007 581 589
37. V. Gruenwald, L. Wilkens, M. Gebel A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results J Clin Oncol 25 Suppl 18S 2007 4598
38. P.A. Philip, M.R. Mahoney, C. Allmer Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer J Clin Oncol 23 2005 6657 6663
39. M.B. Thomas, R. Chadha, K. Glover Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma Cancer 110 2007 1059 1067
40. P.J. O'Dwyer, B.J. Giantonio, D.E. Levy, J.S. Kauh, D.B. Fitzgerald, B. Ab Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's study E1203 J Clin Oncol 24 Suppl 18S 2006 4143
41. R.K. Ramanathan, C.P. Belani, D.A. Singh A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer Cancer Chemother Pharmacol 64 2009 777 783
42. T. Bekaii-Saab, J. Markowitz, N. Prescott A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas Clin Cancer Res 15 2009 5895 5901
43. A. Villanueva, D.Y. Chiang, P. Newell Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
44. L. Chen, H.S. Shiah, C.Y. Chen Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC) J Clin Oncol 27 Suppl 2009 15s (abstract 4587)
45. A.X. Zhu, T.A. Abrams, R. Miksad Phase 1/2 study of everolimus in advanced hepatocellular carcinoma Cancer 117 2011 5094 5102
46. H. Huynh, T.T. Nguyen, K.H. Chow, P.H. Tan, K.C. Soo, E. Tran Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis BMC Gastroenterol 3 2003 19
47. B.H. O'Neil, L.W. Goff, J.S. Kauh Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma J Clin Oncol 29 2011 2350 2356
48. A.L. Cohn, R.K. Kelley, T.S. Yang Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): results from a phase II randomized discontinuation trial (RDT) J Clin Oncol 30 Suppl 4 2012 (abstract 261)
49. S.L. Chan, H.C. Chung, L.Z. Wang Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG) J Clin Oncol 30 Suppl 4 2012 (abstract 259)
50. M. Bitzer, M. Horger, T.M. Ganten Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study J Clin Oncol 30 Suppl 4 2012 (abstract 262)
51. S.M. Wilhelm, C. Carter, L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
52. I. Duran, S.J. Hotte, H. Hirte Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors Clin Cancer Res 13 2007 4849 4857
53. R.S. Finn, R.T.P. Poon, T. Yau Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 29 Suppl 2011 (abstract 4074)
54. W. Sun, D. Nelson, S.R. Alberts Phase Ib study of mapatumumab in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) and chronic viral hepatitis J Clin Oncol 29 Suppl 4 2011 (abstract 261)
55. J.M. Hubbard, S.R. Alberts, W.S. Loui Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745 J Clin Oncol 29 Suppl 2011 (abstract 4116)
56. M.B. Thomas, J.S. Morris, R. Chadha Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma J Clin Oncol 27 2009 843 850
57. P.A. Philip, M.R. Mahoney, K.D. Holen Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer Cancer 118 2011 2424 2430
58. T. Yau, H. Wong, P. Chan Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease Invest New Drugs 2012 Mar 9 [Epub ahead of print]
59. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989
60. G.K. Abou-Alfa, P. Johnson, J.J. Knox Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial JAMA 304 2010 2154 2160
61. A.X. Zhu, L.S. Blaszkowsky, D.P. Ryan Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 1898 1903
62. W. Sun, D. Sohal, D.G. Haller Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma Cancer 117 2011 3187 3192
63. C.H. Hsu, T.S. Yang, C. Hsu Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Br J Cancer 102 2010 981 986
64. A. Asnacios, L. Fartoux, O. Romano Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study Cancer 112 2008 2733 2739
65. H.K. Sanoff, S. Bernard, R.M. Goldberg Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma Gastrointest Cancer Res 4 2011 78 83